News | December 09, 2024
Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Declan brings over 25 years of expertise in the pharmaceutical and biotech sectors
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
The company will address these observations within the stipulated timeline
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
